Imvax Named as a PHL Inno Inaugural Fire Awards Honoree
PHILADELPHIA, PA (August 12, 2022) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced that it has been named an honoree of the inaugural PHL Inno Fire Awards, which recognize the most innovative companies and individuals in the Greater Philadelphia region.
The Fire Awards, Inno’s premiere awards program, showcase the businesses, institutions and individuals with the greatest impacts on or contributions to the local innovation ecosystem. To determine the 20 honorees in the 2022 list, PHL Inno sought nominations from the public as well as suggestions from its editorial team, and selections were made by the publication’s editorial board.
“Innovation is at the core of our work to create cancer immunotherapies to address some of the most difficult-to-treat solid tumors, and so we are honored to be recognized among this list of pioneering Philadelphia companies,” said John P. Furey, Chief Executive Officer. “With a pipeline aimed at addressing multiple types of cancer, our pursuit of innovation continues unabated, driven by the urgency to provide patients with better treatment options.”
About Imvax, Inc.
Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax is headquartered in Philadelphia, PA. For additional information, please visit www.imvax.com.